

# 中新藥業 (600329.CH)

量價雙輪驅動

香港 | 醫藥 | 公司研報



PhillipCapital

12 May 2015

中新藥業是天津醫藥集團下的中藥上市平臺公司，繼承的天津老字型大小中藥品種超過 400 個，擁有品種資源優勢。15 年招標或將加速，公司大部分品種市場競爭格局較好，預期降價壓力較小，中標地區擴大後有望快速放量。


核心品種速效救心丸是全國第一個中成藥規模化生產的滴丸劑，已被列為國家機密配方，並為少數幾個“國寶”級中藥之一。150S 規格的救心丸在內蒙古、甘肅的中標價格已提高到 35 元/盒，提價幅度近 38%。提價後經銷商及終端銷售積極性亦將明顯增強，或將助力其成長為十億級品種，毛率亦或增長升約十個百分點，進而帶動整體盈利能力的提升。

2015 年 1 月底，公司修訂非公開發行 A 股股票預案，擬募集資金總額不超過 8.36 億元，用於終端行銷網路建設、亳州產業園建設和功能性植物飲料專案。總體上，融資項目有望提升公司的行銷能力，並向產業鏈上游延伸。

## 量價雙輪驅動

中新藥業資源優勢豐富，招標提速及行銷改革或促進大品種放量，產品提價將提升盈利能力，我們預期公司業績增長將提速。給予公司對應 15 年每股收益 40 倍估值，目標價為 23.64 元，首予“持有”評級。(現價截至 5 月 8 日)

### Historical P/E valuation



## 優勢品種眾多，招標提速或快速放量

中新藥業是天津醫藥集團下的中藥上市平臺公司，繼承的天津老字型大小中藥品種超過 400 個，擁有品種資源優勢。截止 14 年末，公司擁有 17 個劑型的 601 個藥品批准文號，其中，國寶級中藥 4 個，國家機密品種 1 個，國家秘密品種 3 個，擁有中藥保護品種 8 個，獨家生產品種 101 個，國家基藥品種 85 個，國家醫保品種 267 個。

值得一提的是，國內中藥品種的新藥批文數更是逐年下降，2010 年尚有 166 個中藥品種獲批，2014 年獲批的中藥品種已不足 50 個，體現出中藥企業創新放緩。在這樣的背景下，公司品種資源的價值日益凸顯。

## 持有 (首次)

現價 CNY 22.89

(現價截至 5 月 8 日)

目標價 CNY 23.64 (+3.3%)

### 公司資料

普通股股東 (百萬股):	739
市值 (人民幣百萬元):	16,923
52 周 最高價/最低價 (人民幣):	24.49/ 13.18

### 主要股東, %

天津市醫藥集團有限公司 :	44.26
---------------	-------

### 股價表現, %

	1 個月	3 個月	1 年
中新藥業	-0.13	38.72	67.21
上證指數	<span style="color: red;">-3.94</span>	<span style="color: green;">5.03</span>	<span style="color: red;">-37.37</span>

### 股價 & 上證指數



### 財務資料

CNY mn	FY13	FY14	FY15E	FY16E
Net Sales	6010	7087	8389	9857
Net Profit	352	358	437	522
EPS, CNY	0.48	0.48	0.59	0.71
PER, x	47.69	47.69	38.73	32.39
BVPS, CNY	3.27	3.74	4.13	4.62
P/BV, x	7.00	6.12	5.54	4.96
ROE, %	15.4	13.8	14.1	15.3
Debt/Equity (%)	104.36	84.52	81.16	81.16


Source: Company reports, Phillip Securities Est.

研究分析員

範國和

(+ 86 21 51699400-110)

fanguohe@phillip.com.cn

**Reduced approval number of traditional Chinese medicines**



Source: SFDA, Phillip Securities (HK) Research

2014年，多種因素影響導致基藥招標進展緩慢，直至2015年首季，僅有10個省市完成基藥招標，非基藥招標進展則更為緩慢。不過，15年招標或將加速。中新藥業大部分品種市場競爭格局較好，預期降價壓力較小，中標地區擴大後有望快速放量。

**獨家基藥提價**

公司核心品種速效救心丸是全國第一個中成藥規模化生產的滴丸劑，已被列為國家機密配方，並為少數幾個“國寶”級中藥之一。不過，此前該藥日均使用費用僅為2.5元，遠低於同類品種複方丹參滴丸、通心絡膠囊、腦心通膠囊4.8-11元的費用。目前，全國逾20個省市啓動低價藥的招標，公司150S規格的速效救心丸在內蒙古、甘肅的中標價格已提高到35元/盒，提價幅度近38%。不過，提價後其日用金額亦僅有3.5元，距離5元的低價藥標準仍有逾四成的上升空間。另外，清咽滴丸低價藥招標同樣進行了提價，提價幅度約15%，提價後日用金額約4.3元，未來亦仍有提價空間。

我們以為，速效救心丸在心腦血管領域具有極好的安全性和有效性，上市30年未發現一例毒副作用報導，因此，其剛性需求旺盛，提價應不會影響銷售，而提價後經銷商及終端銷售積極性亦將明顯增強，或將助力其成長為十億級品種。此前，該品種毛率一直維持在68%的高位，而在提價後，毛率或提升約十個百分點，進而帶動整體盈利能力的提升。

**Gross margin is expected to improve**


Source: Company report, Phillip Securities (HK) Research

## 定增融資項目有望彌補短板

2015 年 1 月底，公司修訂非公開發行 A 股股票預案，擬募集資金總額不超過 8.36 億元，用於終端行銷網路建設、亳州產業園建設和功能性植物飲料專案。總體上，融資項目有望提升公司的行銷能力，並向產業鏈上游延伸。

行銷系公司較為薄弱的環節。根據 2015 年經營計畫，行銷建設是亮點，公司將促進大品種增量、加快行銷整合及推進電子商務平臺建設。其中，尤其將彌補速效救心丸終端行銷空白，樹立患者長期服用意識。實際上，速效救心丸在調節血脂、防治動脈硬化和血管狹窄、改善心功能等方面具有治本功效，亦為高效、安全的活血化淤藥物，適用於長期服用。因此，如果公司行銷策略調整適當，速效加速上量值得期待。

## 催化劑

大品種銷售超預期；  
推進國企改革。

## 風險

招標進展低於預期；  
增發項目進展低於預期；  
低價藥提價進度及幅度不及預期。

## 財務報告

FYE	2012	2013	2014	2015F	2016F
<b>Valuation Ratios</b>					
Price Earnings	38.15	47.69	47.69	38.73	32.39
Price to Book	7.92	7.00	6.12	5.54	4.96
Dividend Yield	0.9%	0.7%	0.7%	0.9%	1.0%
<b>Per share data(RMB)</b>					
EPS Adjusted	0.60	0.48	0.48	0.59	0.71
Book Value Per Share	2.89	3.27	3.74	4.13	4.62
Dividends Per Share	0.20	0.15	0.15	0.20	0.22
<b>Growth&amp; Margin</b>					
Revenue growth	-	17.2%	17.9%	18.4%	17.5%
Gross Profit growth	-	7.1%	12.2%	24.5%	18.3%
Net Profit growth	-	-20.1%	1.6%	22.1%	19.6%
<b>Profitability Ratios</b>					
Gross Margin	34.1%	31.2%	29.7%	31.2%	31.4%
Net Profit Margin	8.6%	5.9%	5.0%	5.2%	5.3%
Dividend Payout Ratio %	33.5%	31.5%	31.0%	33.8%	31.1%
<b>Key Ratios</b>					
Return on Assets	10.3%	7.3%	6.7%	7.7%	8.4%
Return on Equity	22.0%	15.4%	13.8%	14.1%	15.3%
Effective Tax Rate	11.4%	13.5%	11.9%	12.0%	12.0%
Liability ratio	48.4%	51.1%	45.8%	44.8%	44.8%
<b>Income Statement(RMB: mn)</b>					
<b>Revenue</b>	<b>5,129</b>	<b>6,010</b>	<b>7,087</b>	<b>8,389</b>	<b>9,857</b>
- Cost of Goods Sold	3,341	4,094	4,936	5,772	6,762
<b>Gross Income</b>	<b>1,749</b>	<b>1,873</b>	<b>2,102</b>	<b>2,617</b>	<b>3,095</b>
- Selling, General & Admin Expenses	1,471	1,520	1,721	2,139	2,514
<b>Operating Income</b>	<b>277</b>	<b>352</b>	<b>381</b>	<b>478</b>	<b>582</b>
- Interest Expense	50	52	48	50	50
- Net Non-Operating Losses (Gains)	-290	-116	-99	-100	-100
<b>Pretax Income</b>	<b>517</b>	<b>417</b>	<b>431</b>	<b>528</b>	<b>632</b>
- Income Tax Expense	59	56	51	63	76
<b>Income Before XO Items</b>	<b>458</b>	<b>361</b>	<b>379</b>	<b>465</b>	<b>556</b>
- Minority Interests	17	9	22	28	33
<b>Net Profit</b>	<b>441</b>	<b>352</b>	<b>358</b>	<b>437</b>	<b>522</b>

Source: Company, Phillip Securities (HK) Research Estimates

(Financial figures as at 8 May 2015)

**PHILLIP RESEARCH STOCK SELECTION SYSTEMS**

Total Return	Recommendation	Rating	Remarks
>+20%	Buy	1	>20% upside from the current price
+5% to +20%	Accumulate	2	+5% to +20% upside from the current price
-5% to +5%	Neutral	3	Trade within ± 5% from the current price
-5% to -20%	Reduce	4	-5% to -20% downside from the current price
<-20%	Sell	5	>20% downside from the current price

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation

**GENERAL DISCLAIMER**

This publication is prepared by Phillip Securities (Hong Kong) Ltd ("Phillip Securities"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This publication should not be relied upon as authoritative without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.

**Disclosure of Interest**

Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report.

Firm's Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.

**Availability**

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited ("PSHK") believed to be accurate. PSHK does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of different product's risks, please visit the Risk Disclosures Statement on <http://www.phillip.com.hk>.

© 2015 Phillip Securities (Hong Kong) Limited

---

**Contact Information (Regional Member Companies)**


---

**SINGAPORE**
**Phillip Securities Pte Ltd**

Raffles City Tower  
 250, North Bridge Road #06-00  
 Singapore 179101  
 Tel : (65) 6533 6001  
 Fax : (65) 6535 6631  
 Website: [www.poems.com.sg](http://www.poems.com.sg)

**HONG KONG**
**Phillip Securities (HK) Ltd**

Exchange Participant of the Stock Exchange of Hong Kong  
 11/F United Centre 95 Queensway  
 Hong Kong  
 Tel (852) 22776600  
 Fax (852) 28685307  
 Websites: [www.phillip.com.hk](http://www.phillip.com.hk)

**INDONESIA**
**PT Phillip Securities Indonesia**

ANZ Tower Level 23B,  
 Jl Jend Sudirman Kav 33A  
 Jakarta 10220 – Indonesia  
 Tel (62-21) 57900800  
 Fax (62-21) 57900809  
 Website: [www.phillip.co.id](http://www.phillip.co.id)

**THAILAND**
**Phillip Securities (Thailand) Public Co. Ltd**

15th Floor, Vorawat Building,  
 849 Silom Road, Silom, Bangrak,  
 Bangkok 10500 Thailand  
 Tel (66-2) 6351700 / 22680999  
 Fax (66-2) 22680921  
 Website: [www.phillip.co.th](http://www.phillip.co.th)

**UNITED KINGDOM**
**King & Shaxson Capital Limited**

6th Floor, Candlewick House,  
 120 Cannon Street,  
 London, EC4N 6AS  
 Tel (44-20) 7426 5950  
 Fax (44-20) 7626 1757  
 Website: [www.kingandshaxson.com](http://www.kingandshaxson.com)

**AUSTRALIA**
**PhillipCapital Australia**

Level 12, 15 William Street,  
 Melbourne, Victoria 3000, Australia  
 Tel (613) 96188238  
 Fax (613) 92002272  
 Website: [www.phillipcapital.com.au](http://www.phillipcapital.com.au)

**MALAYSIA**
**Phillip Capital Management Sdn Bhd**

B-3-6 Block B Level 3 Megan Avenue II,  
 No. 12, Jalan Yap Kwan Seng, 50450  
 Kuala Lumpur  
 Tel (603) 21628841  
 Fax (603) 21665099  
 Website: [www.poems.com.my](http://www.poems.com.my)

**JAPAN**
**PhillipCapital Japan K.K.**

Nagata-cho Bldg.,  
 8F, 2-4-3 Nagata-cho,  
 Chiyoda-ku, Tokyo 100-0014  
 Tel (81-3) 35953631  
 Fax (81-3) 35953630  
 Website: [www.phillip.co.jp](http://www.phillip.co.jp)

**CHINA**
**Phillip Financial Advisory (Shanghai) Co. Ltd**

No 436 Hengfeng Road,  
 Greentech Unit 604,  
 Postal code 200070  
 Tel (86-21) 51699400  
 Fax (86-21) 63532643  
 Website: [www.phillip.com.cn](http://www.phillip.com.cn)

**FRANCE**
**King & Shaxson Capital Limited**

3rd Floor, 35 Rue de la Bienfaisance 75008  
 Paris France  
 Tel (33-1) 45633100  
 Fax (33-1) 45636017  
 Website: [www.kingandshaxson.com](http://www.kingandshaxson.com)

**UNITED STATES**
**Phillip Futures Inc**

141 W Jackson Blvd Ste 3050  
 The Chicago Board of Trade Building  
 Chicago, IL 60604 USA  
 Tel +1.312.356.9000  
 Fax +1.312.356.9005